FORE Biotherapeutics Earns Breakthrough Therapy Designation for Plixorafenib
FORE Biotherapeutics, a registration-stage biopharmaceutical company focused on developing precision therapies for cancer, has announced a significant regulatory milestone for its lead investigational therapy. The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation (BTD) to plixorafenib for the treatment of adult patients with BRAF V600E-mutated high-grade glioma (HGG), a particularly aggressive and difficult-to-treat form of brain cancer. According to the company, this designation may represent the first time a targeted therapy has received BTD specifically for high-grade glioma, highlighting the potential importance of this development for the field of neuro-oncology.
High-grade gliomas, including glioblastoma, are among the most aggressive primary tumors of the central nervous system. Despite advances in surgery, radiation, and chemotherapy, patient outcomes remain poor, with limited survival benefits and significant treatment-related toxicity. These tumors are characterized by rapid growth, resistance to conventional therapies, and substantial impact on neurological function, resulting in high morbidity and mortality. As a result, there is a critical and ongoing need for new treatment approaches that are both more effective and better tolerated.
Plixorafenib is a novel, next-generation BRAF inhibitor designed to target cancers driven by BRAF mutations, particularly the BRAF V600E mutation. Unlike earlier BRAF inhibitors, plixorafenib acts as a “dimer breaker,” meaning it disrupts abnormal signaling pathways in cancer cells more effectively by preventing BRAF protein dimerization. This mechanism is combined with a high degree of selectivity for BRAF alterations, which may contribute to improved anti-tumor activity while minimizing off-target effects.
The FDA’s decision to grant Breakthrough Therapy Designation was based on encouraging clinical data generated from approximately 25 patients treated across a completed Phase 1/2a trial and the ongoing Phase 2 FORTE basket study. The FORTE trial is designed to evaluate plixorafenib in a range of BRAF V600E-mutated central nervous system (CNS) tumors, including high-grade gliomas, low-grade gliomas (LGG), and other primary brain and spinal cord tumors in both adult and pediatric populations.
Breakthrough Therapy Designation is reserved for investigational therapies intended to treat serious or life-threatening conditions where early clinical evidence suggests a substantial improvement over existing treatment options. The designation provides several important advantages, including more frequent interactions with FDA reviewers, involvement of senior regulatory staff, and eligibility for rolling submission and priority review of a future marketing application. Collectively, these benefits are designed to accelerate the development and regulatory review process, potentially bringing promising therapies to patients more quickly.
Clinical data supporting the designation have demonstrated notable anti-tumor activity for plixorafenib in patients with BRAF-altered CNS tumors. Results presented at major scientific meetings, including the ASCO 2023 and the SNO 2023, showed that the drug achieved a 67% overall response rate (ORR) in a pre-specified subgroup of patients with refractory, MAPK inhibitor-naïve BRAF V600-mutated primary CNS tumors. These findings were further supported by additional efficacy measures such as duration of response (DOR) and clinical benefit rate (CBR), indicating sustained and meaningful clinical activity across different tumor types and CNS histologies.
Importantly, the ongoing FORTE study has reached a key interim milestone. The BRAF V600E primary CNS tumor cohort met pre-specified criteria during interim analysis, prompting the Independent Data Monitoring Committee (IDMC) to recommend continuation of the trial as planned. This decision was based on positive response data assessed through blinded independent central review (BICR), along with ongoing safety monitoring. The IDMC’s support reinforces confidence in the study’s design and the therapeutic potential of plixorafenib.
Medical experts in the field have emphasized the urgent need for innovation in the treatment of high-grade gliomas. Dr. Macarena de la Fuente, Chief of the Neuro-Oncology Division at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, noted that these tumors are associated with poor clinical outcomes despite the use of multimodal treatment strategies. She highlighted that patients not only face a limited prognosis but also experience significant side effects from current therapies, underscoring the importance of developing new treatments that can improve both efficacy and tolerability.
From the company’s perspective, the BTD represents a major validation of plixorafenib’s differentiated mechanism of action and its emerging clinical profile. Dr. Stacie Peacock Shepherd, Chief Medical Officer of FORE Biotherapeutics, stated that the designation reinforces confidence in the therapy’s potential to address difficult-to-treat cancers driven by BRAF mutations. She emphasized that BRAF alterations are increasingly recognized as actionable drivers in the molecularly guided treatment of high-grade gliomas, making targeted therapies like plixorafenib an important area of focus.
In addition to its activity in high-grade gliomas, plixorafenib has demonstrated a differentiated profile across a broader range of primary CNS tumors, including glioblastoma and other malignancies. As data from the FORTE trial continue to mature, the company expects to further validate these findings and better define the therapy’s benefit-risk profile across different patient populations.
The Breakthrough Therapy Designation builds on prior regulatory recognitions for plixorafenib. The therapy has already received Fast Track Designation for the treatment of cancers harboring BRAF Class 1 (V600) and Class 2 (including fusion) alterations in patients who have exhausted existing treatment options. Additionally, it has been granted Orphan Drug Designation for the treatment of primary brain and CNS malignancies, reflecting its potential to address rare and underserved patient populations.
Together, these designations provide a strong regulatory framework to support the continued development of plixorafenib. They also highlight the growing importance of biomarker-driven approaches in oncology, where treatments are tailored to specific genetic alterations rather than broad tumor types. In the case of BRAF-mutated CNS tumors, this approach may offer new hope for patients who have historically had very limited therapeutic options.
Looking ahead, FORE Biotherapeutics plans to continue advancing the FORTE basket trial, which includes multiple cohorts of patients with different BRAF-altered malignancies. The study is expected to generate a more comprehensive data set that can support potential regulatory submissions and inform future clinical development strategies.
In conclusion, the FDA’s granting of Breakthrough Therapy Designation to plixorafenib represents a significant advancement in the development of targeted therapies for high-grade glioma and other BRAF-mutated CNS tumors. With promising early clinical data, multiple regulatory designations, and an ongoing pivotal study, plixorafenib is emerging as a potentially transformative treatment option in a field where innovation is urgently needed. As development progresses, the oncology community will be closely watching for further data that could help redefine the standard of care for patients with these challenging and life-threatening cancers.
About the Global Phase 2 FORTE Basket Study
The registration-intended FORTE Master Protocol is a global Phase 2 clinical trial which includes four sub-protocol baskets evaluating plixorafenib in distinct patient populations. The three monotherapy indications currently under evaluation are recurrent or progressive BRAF V600 primary CNS tumors, solid tumors with BRAF fusions and rare BRAF V600 mutated solid tumors. As part of the Bayesian adaptive design of the trial, interim efficacy analyses are conducted in each basket, for which the company reported a positive outcome from the BRAF V600 CNS basket in the third quarter of 2025.
About BRAF Altered Recurrent Primary CNS Tumors
BRAF altered recurrent primary CNS tumors represent a high unmet medical need and a large market opportunity for plixorafenib. In the advanced treatment setting, patients are offered currently approved therapies, but those therapies have significant limitations in efficacy, tolerability, and safety.
About Plixorafenib
Plixorafenib is a novel BRAF inhibitor, with a unique mechanism of action that functions both as a dimer and paradox breaker, and that has demonstrated a differentiated and compelling monotherapy profile in clinical studies. In a previously conducted Phase 1/2 study, in patients with MAPK inhibitor naïve BRAF V600 primary recurrent CNS tumors (n=9), plixorafenib monotherapy demonstrated an ORR of 67% and a clinical benefit rate of greater than 75%. In patients with V600 alterations who were MAPK inhibitor naïve, plixorafenib achieved a 42% response rate with prolonged duration of response (mDOR 17.8 months), with a clinical benefit rate of >70%.
Plixorafenib also demonstrated a favorable safety and tolerability profile across tumor types, including relative to existing standard of care treatments for various BRAF altered tumors, with a discontinuation rate due to drug-related adverse events of less than 2%. Fore believes plixorafenib has the potential to overcome the limitations of currently available BRAF inhibitors through its unique mechanism of action targeting BRAF, while avoiding the limitations of the earlier generation BRAF inhibitors that led to rapid recurrence of disease and the need for combination with a MEK inhibitor.
About FORE Biotherapeutics
Fore is a registration stage targeted oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company’s lead asset plixorafenib (FORE8394; formerly PLX8394) is a V600 and non-V600 BRAF inhibitor rationally designed with a first-in-class mechanism to address treatment gaps from 1st and 2nd generation BRAF inhibitors.
Source Link:https://www.businesswire.com/
